The Zhitong Finance App learned that VVardis Holding (VVVV.US), which sells proprietary non-invasive cavities treatment products, announced the IPO terms last Friday. The Zug, Switzerland-based company plans to issue 9.5 million shares in the price range of $21-24, and raise $214 million. In terms of the median range, VVardis Holding's market capitalization is approximately $1.3 billion.

VVardis develops and sells Curodont—a peptide-based treatment for early cavities that can be performed in 5 minutes or less in a dental clinic without drilling or injections. Its American product Curodont Repair Fluoride Plus is sold as an over-the-counter drug according to the FDA monograph (monograph), contributing most of the company's revenue; a fluoride-free version, Curodont Repair, is sold as a medical device in the UK and parts of Europe. In the US, the company distributes exclusively through Henry Schein and is supported by its own sales team.

VvarDis Holding was founded in 2020 with 12-month revenue ending June 30, 2026 of $50 million. The company intends to be listed on the New York Stock Exchange under the code VVVV. Goldman Sachs, J.P. Morgan Chase, William Blair, UBS Investment Banking and Deutsche Bank acted as joint bookkeepers for this transaction. The estimated pricing period is for the week of November 9, 2026 (Monday).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.